Meeting
2023 ASCO Annual Meeting
Uncovering mechanisms of response of pembrolizumab and lenvatinib for the treatment of platinum-resistant high grade serous ovarian cancer.
Authors
Jeffrey How
University of Texas MD Anderson Cancer Center, Houston, TX
Jeffrey How , Shannon Neville Westin , Travis T. Sims , Kathryn Lito , Joseph Celestino , Kelly M. Rangel , Weiyi Peng , Linghua Wang , Amir A. Jazaeri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT05114421
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS5619)
DOI
10.1200/JCO.2023.41.16_suppl.TPS5619
Abstract #
TPS5619
Poster Bd #
310b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.
First Author: Maliheh Mohamadpour
Poster
2024 ASCO Annual Meeting
Neoadjuvant pembrolizumab plus lenvatinib in patients with resectable stage III melanoma (NeoPele): Analysis of tumor microenvironment (TME) correlated to pathological response.
First Author: Ines Esteves Domingues Pires Da Silva
Poster
2024 ASCO Annual Meeting
Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC): Preliminary findings.
First Author: Benjamin Adam Weinberg
Poster
2024 ASCO Annual Meeting
A phase II trial to assess the impact of β2 adrenergic blockade in immune checkpoint inhibitor (ICI)– refractory metastatic triple negative breast cancer (mTNBC).
First Author: Shipra Gandhi